hCG vs hMG vs enclomiphene: what each one is and does
Reviewed 21 sourcesPublished by PepVault
hCG stands in for LH, hMG adds FSH for sperm, enclomiphene makes your own pituitary send both. What each is approved for and what its trials measured.

- Last reviewed
- Sources
- 21
- Questions
- 6
- Compounds
- 3
The short answer
hCG stands in for LH, the signal that tells the testes to make testosterone. hMG (menotropins) supplies FSH and LH together, the pair that drives sperm production. Enclomiphene is a pill that makes your own pituitary send more LH and FSH. In the US, hCG is approved for men whose low testosterone starts in the pituitary, hMG only for women, and enclomiphene for nothing.
Evidence: hCG and hMG are FDA-approved biologics with decades of clinical use; enclomiphene has phase 3 randomized trials on hormone and sperm measures but no approval anywhere; the hCG-plus-hMG fertility data in men are cohort studies.

What are hCG, hMG and enclomiphene?
Two are injected hormones; one is a pill that changes how your brain reads a hormone.
- hCG (human chorionic gonadotropin) is the pregnancy hormone. The US products are purified from the urine of pregnant women, and the labels say its action is virtually identical to LH (luteinizing hormone), the pituitary signal that tells the Leydig cells of the testes to make testosterone, with a small amount of FSH-like activity12. Ovidrel, a version made in hamster cells, is approved only for women18.
- hMG (human menopausal gonadotropin, or menotropins) is extracted from the urine of postmenopausal women, whose pituitaries make a lot of both gonadotropins. Each vial of Menopur, the US product, carries 75 IU of FSH (follicle-stimulating hormone) activity and 75 IU of LH activity, and the label notes that hCG is detected in it3. FSH is the signal that supports sperm production.
- Enclomiphene is the trans form of clomiphene, one of its two geometric isomers (the same atoms in two shapes)21. Both are oral SERMs (selective estrogen receptor modulators): drugs that block estrogen in some tissues13. It blocks estrogen's feedback signal in the hypothalamus, so the brain reads estrogen as low and the pituitary sends out more of the body's own LH and FSH13. It is not a peptide and not a hormone.

hCG and hMG are gonadotropins, the hormones that drive the testes and ovaries; enclomiphene raises your own.

Where does each one act?
The hypothalamus sends GnRH, the pituitary answers with LH and FSH, and the testes answer LH by making testosterone and FSH, with that testosterone, by making sperm. Each drug enters the chain at a different link.
| Question | hCG | hMG (menotropins) | Enclomiphene |
|---|---|---|---|
| Acts on | The testes, directly | The testes, directly | The brain's estrogen sensor, upstream of the pituitary |
| Signal it supplies | LH-like | FSH and LH | Raises your own LH and FSH |
| Needs a working pituitary? | No | No | Yes |
| How it is taken | Injection into a muscle on the US labels12 | Injection under the skin on the US label3 | Oral capsule, once daily in its trials89 |
| What its studies showed | Kept testosterone inside the testes near its normal level on TRT14 | Added to hCG, starts sperm production in men who make none1516 | Kept sperm counts in range in its trials, where testosterone gel lowered them12 |

The pituitary row is the practical one. Enclomiphene works only if the pituitary can still answer, so it has nothing to work with in a man whose pituitary is damaged, or whose LH is switched off by outside testosterone. hCG and hMG skip the pituitary entirely, which is why they work in both cases.
hCG lingers. In 18 women whose own gonadotropins were switched off, one shot peaked about 20 hours later, had an elimination half-life of 32 to 33 hours whether given into muscle or under the skin, and fell below a tenth of its peak within 8 days19. That fits the two-to-three-times-a-week schedules on the labels and in the studies14. Menopur's FSH has an elimination half-life of 11 to 13 hours on its label3.
Try it
How HCG builds up
An estimate from a half-life of about 33 hours, one dose a day for four weeks. The shape of the level, not a measurement.
What is each one approved for?
Here they split most sharply.
| Drug | US approval | Approved uses |
|---|---|---|
| hCG (Pregnyl, Novarel) | Yes | Undescended testes in boys; selected cases of hypogonadotropic hypogonadism (low testosterone because the pituitary is not sending LH) in men; triggering ovulation in women12 |
| Recombinant hCG (Ovidrel) | Yes | Women only: final egg maturation in IVF and ovulation induction18 |
| hMG (Menopur) | Yes, women only | Developing multiple follicles in ovulatory women as part of IVF and similar programs3 |
| hMG (Menopur, UK) | Not a US approval | Also men with hypogonadotropic hypogonadism, given with hCG, to stimulate sperm production4 |
| Enclomiphene | No | None; the FDA sent a complete response letter in 2015 and the EU refused it in 201867 |

Three things surprise people. First, both hCG labels state in capitals that hCG has not been shown to work for obesity and has no known effect on fat, appetite or hunger12. Second, the US has no approved hMG for men. Older US menotropins brands, Pergonal, Humegon and Repronex, are listed as discontinued, and Menopur, approved in 2004, is labelled for women53. In the UK, the same product's label covers men, and it describes the sequence: hCG first, at 1,000 to 2,000 IU two to three times a week, then menotropins added at 75 or 150 IU two or three times weekly, for at least 3 or 4 months4. Men with primary testicular failure, where the testes themselves cannot answer, usually do not respond4.
Third, enclomiphene met its testosterone targets and was still turned down. Its maker said the FDA's letter found the phase 3 design no longer adequate to show clinical benefit, recommended more phase 3 studies, and raised concerns about entry criteria, dose titration and the validation of the lab methods6. The EU regulator said the studies did not look at whether symptoms such as bone strength, weight gain, impotence and libido improved, noted a risk of venous thromboembolism (blood clots in the veins), and concluded the benefits did not outweigh the risks7.
What did the enclomiphene trials measure?
Blood numbers and sperm counts, not how men felt: the program's strength, and the reason regulators said no. The men were overweight, 18 to 60, with secondary hypogonadism (low testosterone with low or normal LH)89.
| Trial | Compared | Main measure | Result |
|---|---|---|---|
| ZA-3018 | 12.5 or 25 mg daily vs placebo, 12 weeks | Share with 24-hour average testosterone in the 300 to 1,040 ng/dL range | 78.8% of 113 men on enclomiphene |
| ZA-3029 | Same design | Same | 81.3% of 134 men on enclomiphene |
| ZA-301 and ZA-30289 | Same | Share whose sperm concentration fell by half or more | 14.2% on enclomiphene in both; 2.6% and 4.3% on placebo |
| ZA-304 and ZA-305101112 | 12.5 or 25 mg vs AndroGel 1.62% vs placebo, 16 weeks | Normal testosterone plus sperm at 15 million/mL or more | Testosterone rose in every treatment group; LH and FSH rose on enclomiphene and fell on gel; sperm stayed in range on enclomiphene and fell sharply on gel |
The sperm rows say two things. Against testosterone gel, enclomiphene protected sperm. Against placebo, about one man in seven on enclomiphene still saw his sperm concentration halve89. Both trials listed that measure as a primary outcome, beside testosterone.
A 2025 meta-analysis pooled randomized trials of enclomiphene and clomiphene in men. Against placebo, total testosterone came out 273.76 ng/dL higher, LH 4.66 IU/L higher and FSH 4.59 IU/L higher; against testosterone gel, testosterone did not differ, while LH and FSH were higher13. The two drugs were pooled, so those numbers are for the class.
PepVault's bloodwork log records total and free testosterone, LH, FSH, estradiol and hematocrit, so each draw sits beside the one before it. Log it in PepVault
What did the hCG and hMG studies measure?
Different jobs: hCG alone to hold testosterone inside the testes, and hCG plus hMG to start sperm in men whose pituitary sends nothing.
hCG on TRT. In a 3-week randomized study, 29 healthy men took 200 mg of testosterone enanthate a week plus placebo or hCG every other day. LH and FSH fell to 5% and 3% of baseline, and on placebo the testosterone inside the testes fell 94%, from 1,234 to 72 nmol/L. With 250 IU of hCG every other day it ended 7% below baseline; with 500 IU, 26% above14. At baseline, blood testosterone was only 1.2% of the level inside the testes, the level sperm production depends on14.
hCG plus hMG, from no sperm. In 223 men with congenital hypogonadotropic hypogonadism who had never gone through puberty, combined hCG and hMG grew the testes from 2.1 to 8.1 mL on average, raised testosterone from 0.9 to 15.1 nmol/L, and brought sperm into the semen in 64%, with sperm first appearing at a median of 15 months; 19 of the 34 men who wanted children got their partners pregnant during treatment16. A German series of 42 men, treated with hCG plus hMG or with a GnRH pump, saw sperm appear in 54 of 57 courses and pregnancies in 26 of 36, with the two approaches no different in time to sperm or pregnancy rates in men whose cause was in the hypothalamus15.
hMG where hCG alone had failed. In a small UK study, men with hypogonadotropic hypogonadism who had not produced sperm on hCG alone injected hMG under the skin themselves; 6 of the 7 seeking fertility reached sperm counts above 10 million/mL17.
Menopur's US approval rests on a trial in women: 373 women undergoing IVF were randomized to it, and 23% had a continuing pregnancy, a result non-inferior to recombinant FSH3. No trial we found has compared enclomiphene with hMG, or all three drugs head to head.
Which one fits which situation?
Two questions sort them: does the pituitary still work, and is the goal testosterone or sperm?
- Pituitary works, LH low or normal, fertility matters: this is the group the enclomiphene trials enrolled, and the group clomiphene is used for off-label8920.
- On TRT, keeping the testes working: low-dose hCG is the agent studied, because outside testosterone switches off LH and enclomiphene has nothing to amplify14.
- Pituitary not sending LH or FSH, sperm wanted: hCG first, then hMG added for FSH, as the UK Menopur label and the cohort studies describe41516.
- Testes that cannot respond (primary failure): the UK Menopur label says these men usually do not respond, and all three end at the testes4.
Commonly reported: on enclomiphene, more energy and libido over a few weeks, with irritability or visual disturbances making some stop; on hCG beside TRT, testes that regain size and fullness, and puffiness or tender nipples when estradiol climbs. Few non-clinic users report on hMG, which is almost always run by a fertility clinic.
For your own labs: both hCG labels warn that hCG can cross-react in gonadotropin tests, especially LH, and ask that the lab be told12.
In PepVault you can set reminders for an every-few-days shot or a daily capsule, and log each one as it happens. Set reminders in PepVault
When to get help On enclomiphene or clomiphene, leg swelling or pain or sudden shortness of breath (a possible blood clot7), or blurred vision, spots or flashes21, are reasons to call a doctor the same day.
Sources
- Pregnyl (chorionic gonadotropin) prescribing information, Organon. DailyMed, published Dec 4, 2025. dailymed.nlm.nih.gov
- Novarel (chorionic gonadotropin) prescribing information, Ferring. DailyMed, published Sep 25, 2025. dailymed.nlm.nih.gov
- Menopur (menotropins for injection) prescribing information, Ferring. DailyMed, published May 11, 2026. dailymed.nlm.nih.gov
- Menopur 75 IU powder and solvent for solution for injection, Summary of Product Characteristics (UK), revised Jun 3, 2026. emc. medicines.org.uk
- Drugs@FDA (openFDA): menotropins applications, Pergonal BLA 017646, Humegon BLA 020328, Repronex BLA 021047 (discontinued), Menopur BLA 021663 (approved Oct 29, 2004). api.fda.gov
- Repros Therapeutics. Repros receives complete response letter from FDA for enclomiphene. Form 8-K press release, Dec 1, 2015. sec.gov
- European Medicines Agency. EnCyzix (enclomiphene): refusal of the marketing authorisation, 2018. ema.europa.eu
- ZA-301: Phase III study of morning testosterone normalization in men with secondary hypogonadism. ClinicalTrials.gov NCT01532414 (Repros Therapeutics), results. clinicaltrials.gov
- ZA-302: Phase III study of morning testosterone normalization in overweight men with secondary hypogonadism. ClinicalTrials.gov NCT01739595 (Repros Therapeutics), results. clinicaltrials.gov
- ZA-304: Enclomiphene 12.5 or 25 mg vs AndroGel 1.62% vs placebo in acquired hypogonadotropic hypogonadism. ClinicalTrials.gov NCT01993212 (Repros Therapeutics). clinicaltrials.gov
- ZA-305: Enclomiphene 12.5 or 25 mg vs AndroGel 1.62% vs placebo in acquired hypogonadotropic hypogonadism. ClinicalTrials.gov NCT01993225 (Repros Therapeutics). clinicaltrials.gov
- Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016. PubMed 26496621
- Hohl A et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2025. PubMed 41066380
- Coviello AD et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005. PubMed 15713727
- Büchter D et al. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol. 1998. PubMed 9758439
- Liu Z et al. Efficacy and outcome predictors of gonadotropin treatment for male congenital hypogonadotropic hypogonadism: a retrospective study of 223 patients. Medicine (Baltimore). 2016. PubMed 26945370
- Jones TH, Darne JF. Self-administered subcutaneous human menopausal gonadotrophin for the stimulation of testicular growth and the initiation of spermatogenesis in hypogonadotrophic hypogonadism. Clin Endocrinol (Oxf). 1993. PubMed 8435901
- Ovidrel (choriogonadotropin alfa injection) prescribing information, EMD Serono. DailyMed, published Dec 28, 2023. dailymed.nlm.nih.gov
- Mannaerts BM, Geurts TB, Odink J. A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration. Hum Reprod. 1998. PubMed 9688371
- Kaminetsky J et al. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. 2013. PubMed 23530575
- Clomiphene citrate tablets prescribing information, Accord Healthcare. DailyMed, published Nov 9, 2026. dailymed.nlm.nih.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.